PRKD1 (Ab-738) Antibody

What is the molecular target of PRKD1 (Ab-738) Antibody?

PRKD1 (Ab-738) Antibody specifically targets serine/threonine-protein kinase D1, also known as PKC mu/PKD, a critical enzyme that converts transient diacylglycerol (DAG) signals into prolonged physiological effects downstream of PKC. This kinase is involved in multiple cellular pathways including regulation of MAPK8/JNK1 and Ras signaling, Golgi membrane integrity and trafficking, cell survival through NF-kappa-B activation, cell migration, and cell differentiation . The antibody specifically recognizes the peptide sequence around amino acids 736-740 (E-K-S-F-R) derived from human PKD/PKCμ .

What is the host species and clonality of PRKD1 (Ab-738) Antibody?

PRKD1 (Ab-738) Antibody is a rabbit polyclonal antibody developed using synthetic peptide immunogens conjugated to Keyhole Limpet Haemocyanin (KLH) . The polyclonal nature provides multiple epitope recognition, which can enhance signal detection in various applications. The antibodies were produced by immunizing rabbits and subsequently purified by affinity-chromatography using epitope-specific peptide, ensuring high specificity to the target protein .

What species reactivity has been validated for PRKD1 (Ab-738) Antibody?

The PRKD1 (Ab-738) Antibody has been validated for reactivity with human, mouse, and rat samples . This cross-species reactivity makes it versatile for comparative studies across different model organisms. Validation experiments have confirmed that the antibody detects endogenous levels of total PKD/PKCμ protein, making it suitable for physiologically relevant research applications .

What applications has PRKD1 (Ab-738) Antibody been validated for?

PRKD1 (Ab-738) Antibody has been validated for multiple research applications including:

The antibody has demonstrated successful detection of endogenous PRKD1 protein across these applications, with specific validated examples including Western blot analysis of extracts from HeLa, 293, THP1, and JK cells, as well as immunofluorescence staining of methanol-fixed HeLa cells .

What is the optimal Western blotting protocol for PRKD1 (Ab-738) Antibody?

For optimal Western blotting results with PRKD1 (Ab-738) Antibody, follow this methodological approach:

• Sample preparation: Extract proteins from cells using standard lysis buffer containing protease inhibitors

• Protein separation: Resolve 20-50 μg of protein by SDS-PAGE (10% gel recommended)

• Transfer: Transfer proteins to PVDF or nitrocellulose membrane

• Blocking: Block membrane with 5% non-fat milk in TBST for 1 hour at room temperature

• Primary antibody incubation: Dilute PRKD1 (Ab-738) Antibody 1:500-1:1000 in blocking buffer and incubate overnight at 4°C

• Washing: Wash membrane 3-5 times with TBST, 5 minutes each

• Secondary antibody: Incubate with HRP-conjugated anti-rabbit secondary antibody (1:5000-1:10000) for 1 hour at room temperature

• Detection: Develop using enhanced chemiluminescence (ECL) reagent and image using appropriate detection system

This protocol has been validated with cell extracts from HeLa, 293, THP1, and JK cells, confirming specific detection of the PRKD1 protein .

How should immunofluorescence experiments be conducted with PRKD1 (Ab-738) Antibody?

For immunofluorescence analysis using PRKD1 (Ab-738) Antibody:

• Cell preparation: Culture cells on coverslips to 70-80% confluence

• Fixation: Fix cells with methanol for 10 minutes at -20°C (methanol fixation has been specifically validated with this antibody)

• Permeabilization: If using paraformaldehyde fixation instead, permeabilize with 0.1% Triton X-100 for 10 minutes

• Blocking: Block with 1-5% BSA in PBS for 30-60 minutes at room temperature

• Primary antibody: Dilute PRKD1 (Ab-738) Antibody 1:100-1:200 in blocking solution and incubate for 1-2 hours at room temperature or overnight at 4°C

• Washing: Wash 3 times with PBS, 5 minutes each

• Secondary antibody: Incubate with fluorophore-conjugated anti-rabbit secondary antibody at recommended dilution for 1 hour at room temperature

• Counterstaining: Counterstain with DAPI for nuclear visualization

• Mounting: Mount using appropriate anti-fade mounting medium

• Imaging: Analyze using fluorescence microscopy

This method has been validated with methanol-fixed HeLa cells showing specific localization patterns of PRKD1 .

How can non-specific binding be reduced when using PRKD1 (Ab-738) Antibody?

Non-specific binding is a common challenge when working with antibodies. To minimize this issue with PRKD1 (Ab-738) Antibody:

• Optimize blocking conditions: Test different blocking agents (BSA, casein, or commercial blockers) and concentrations (3-5%)

• Adjust antibody dilution: Start with the recommended 1:500-1:1000 for WB or 1:100-1:200 for IF, but optimize based on signal-to-noise ratio

• Include detergents: Add 0.1-0.3% Tween-20 in washing and antibody diluent buffers

• Increase washing stringency: Perform additional washes or extend washing times

• Pre-absorb the antibody: If cross-reactivity is a concern, pre-incubate with lysates from cells lacking the target protein

• Validate with controls: Always include positive and negative controls to distinguish specific from non-specific signals

• For Western blotting: Consider reducing primary antibody incubation time or using a higher dilution if background is excessive

These optimization strategies have been effective in enhancing specificity when using this antibody across different experimental systems .

What are the optimal storage conditions for maintaining PRKD1 (Ab-738) Antibody activity?

To maintain optimal activity of PRKD1 (Ab-738) Antibody:

• Store the antibody at -20°C or -80°C upon receipt

• Avoid repeated freeze-thaw cycles, which can degrade antibody quality and reduce binding efficiency

• For working solutions, store at 4°C for short-term use (1-2 weeks)

• The antibody is supplied at 1.0 mg/mL in phosphate buffered saline (without Mg²⁺ and Ca²⁺), pH 7.4, with 150 mM NaCl, 0.02% sodium azide, and 50% glycerol

• Consider preparing small aliquots for single use to minimize freeze-thaw cycles

• Monitor for signs of precipitation or contamination before use

Following these storage recommendations will help maintain antibody activity and ensure consistent experimental results over time .

What controls should be included when using PRKD1 (Ab-738) Antibody in experimental designs?

Proper controls are essential for antibody-based experiments. When using PRKD1 (Ab-738) Antibody, include:

• Positive control: Lysates from cell lines known to express PRKD1 (validated examples include HeLa, 293, THP1, and JK cells)

• Negative control: Samples where the target protein is absent or knocked down (PRKD1 knockdown cells)

• Loading control: Detect housekeeping proteins (e.g., GAPDH, β-actin) to ensure equal sample loading

• Primary antibody omission: To assess background from secondary antibody

• Isotype control: Use normal rabbit IgG at the same concentration to assess non-specific binding

• Peptide competition: Pre-incubate antibody with immunizing peptide to confirm specificity

• For gene silencing experiments: Include appropriate siRNA/shRNA controls along with scrambled controls

These controls help validate results and ensure that observed signals are specific to PRKD1 protein detection .

How can PRKD1 (Ab-738) Antibody be used to study PRKD1 epigenetic silencing in cancer research?

PRKD1 gene promoter is frequently methylated in invasive breast cancer, leading to its silencing. To investigate this epigenetic regulation using PRKD1 (Ab-738) Antibody:

• Experimental design:

  • Treat breast cancer cell lines (e.g., MDA-MB-231) with DNA methyltransferase inhibitors like decitabine

  • Compare PRKD1 expression in treated versus untreated cells

  • Analyze both methylation status and protein expression

• Protocol approach:

  • Confirm PRKD1 promoter methylation status using methylation-specific PCR

  • Treat cells with decitabine at appropriate concentrations (typically 1-5 μM)

  • Extract proteins at various time points post-treatment

  • Perform Western blotting with PRKD1 (Ab-738) Antibody to detect protein reexpression

  • Conduct parallel immunofluorescence to assess cellular localization

• Data analysis:

  • Quantify protein levels relative to untreated controls

  • Correlate protein expression with promoter methylation status

  • Assess functional consequences using invasion assays

This approach has successfully demonstrated that decitabine treatment can reverse PRKD1 promoter methylation, restore PKD1 expression, and block tumor spread and metastasis in breast cancer models .

What are the methodological considerations for using PRKD1 (Ab-738) Antibody in phosphorylation studies?

When investigating PRKD1 phosphorylation states:

• Phosphatase inhibitors: Include comprehensive phosphatase inhibitor cocktails in lysis buffers to preserve phosphorylation status

• Sample handling: Process samples quickly and maintain cold temperatures throughout

• Activation studies: Compare serum-starved versus stimulated conditions (e.g., PMA, growth factors) to capture dynamic phosphorylation changes

• Complementary antibodies: Use in conjunction with phospho-specific antibodies (e.g., phospho-S738 PKD1) to distinguish total from phosphorylated protein pools

• Phosphatase treatments: Include control samples treated with lambda phosphatase to confirm phosphorylation-dependent signals

• Kinase inhibitors: Use specific PKC inhibitors to confirm pathway-specific phosphorylation

• Detection methods: Consider using phos-tag gels for enhanced separation of phosphorylated species

For comprehensive phosphorylation analysis, researchers can use PRKD1 (Ab-738) Antibody to detect total protein while using phospho-specific antibodies like anti-PKC mu/PKD (phospho S738) to identify specific phosphorylated forms .

How can PRKD1 (Ab-738) Antibody be utilized in studying cellular localization and trafficking of PRKD1?

PRKD1 dynamically relocates between cellular compartments during signaling. To study these dynamics:

• Live-cell imaging approach:

  • Establish cell lines expressing fluorescently-tagged PRKD1

  • Validate expression pattern matches endogenous protein using PRKD1 (Ab-738) Antibody immunofluorescence

  • Apply stimuli known to activate PKD1 signaling

  • Track localization changes over time

• Fixed-cell co-localization:

  • Perform double immunofluorescence with PRKD1 (Ab-738) Antibody and markers for:

    • Golgi apparatus (e.g., GM130)

    • Plasma membrane (e.g., Na⁺/K⁺-ATPase)

    • Nucleus (e.g., DAPI)

    • Mitochondria (e.g., TOM20)

  • Use 1:100-1:200 dilution of PRKD1 (Ab-738) Antibody

  • Analyze co-localization using confocal microscopy and quantitative image analysis

• Subcellular fractionation:

  • Separate cellular compartments using differential centrifugation

  • Analyze PRKD1 distribution by Western blotting using PRKD1 (Ab-738) Antibody

  • Include compartment-specific markers to confirm fraction purity

These approaches can reveal important insights into PRKD1 trafficking between the Golgi, plasma membrane, and nucleus during cellular processes like secretion, proliferation, and stress responses .

How does PRKD1 contribute to Golgi membrane integrity and trafficking?

PRKD1 plays a critical role in maintaining Golgi structure and function. Research using PRKD1 (Ab-738) Antibody has helped elucidate these mechanisms:

• Golgi membrane integrity:

  • PRKD1 acts downstream of heterotrimeric G-protein beta/gamma-subunit complex

  • It maintains structural integrity of Golgi membranes

  • In the trans-Golgi network (TGN), PRKD1 regulates the fission of transport vesicles destined for the plasma membrane

• Molecular mechanism:

  • PRKD1 activates lipid kinase phosphatidylinositol 4-kinase beta (PI4KB) at the TGN

  • This activation leads to local synthesis of phosphorylated inositol lipids

  • These lipids induce sequential production of diacylglycerol (DAG), phosphatidic acid (PA), and lyso-PA (LPA)

  • This lipid cascade is necessary for membrane fission and generation of specific transport carriers

• Experimental approach to study this function:

  • Immunolocalization of PRKD1 at the Golgi using PRKD1 (Ab-738) Antibody

  • Depletion studies (siRNA knockdown) followed by analysis of Golgi morphology

  • Rescue experiments with wild-type versus kinase-dead PRKD1 constructs

  • Trafficking assays to monitor protein transport along the secretory pathway

Understanding PRKD1's role in Golgi function has implications for secretory pathways in normal and disease states .

What is the role of PRKD1 in cancer progression and metastasis?

PRKD1 functions as a tumor suppressor in certain cancers, particularly breast cancer. Studies employing PRKD1 (Ab-738) Antibody have revealed:

• Expression patterns in cancer:

  • PRKD1 expression is frequently downregulated in invasive breast cancer

  • Gene silencing occurs through promoter hypermethylation

  • Loss of expression correlates with increased tumor aggressiveness

• Mechanistic role in invasion:

  • PRKD1 negatively regulates cell motility and invasion

  • It influences actin cytoskeleton dynamics and cell-matrix interactions

  • Loss of PRKD1 promotes epithelial-to-mesenchymal transition

• Experimental evidence:

  • Orthotopic animal models show that PRKD1 knockdown increases local invasion and metastasis to the lung

  • Treatment with DNA methyltransferase inhibitor decitabine reverses PRKD1 silencing and blocks metastasis in a PKD1-dependent manner

  • This anti-metastatic effect is specifically attributed to PRKD1 reexpression

• Clinical correlations:

  • PRKD1 promoter methylation increases with tumor aggressiveness

  • Analysis of human tissue samples shows progressive loss of PKD1 expression from normal tissue to ductal carcinoma in situ to invasive carcinomas

These findings suggest PRKD1 as a potential therapeutic target, where restoration of its expression could inhibit cancer progression and metastasis .

How does PRKD1 integrate with MAPK and NF-κB signaling pathways?

PRKD1 serves as a key integrator of multiple signaling networks:

• MAPK pathway interaction:

  • PRKD1 phosphorylates the epidermal growth factor receptor (EGFR) on dual threonine residues

  • This phosphorylation suppresses EGF-induced MAPK8/JNK1 activation and subsequent JUN phosphorylation

  • PRKD1 also phosphorylates RIN1, inducing its binding to 14-3-3 proteins (YWHAB, YWHAE, YWHAZ)

  • This creates increased competition with RAF1 for binding to GTP-bound Ras proteins (NRAS, HRAS, KRAS)

  • Through these mechanisms, PRKD1 modulates MAPK-dependent cellular responses

• NF-κB pathway regulation:

  • PRKD1 activation leads to NF-κB activation

  • This contributes to cell survival responses, particularly under oxidative stress

  • PRKD1 is involved in resistance to oxidative stress through NF-κB activation

• Experimental approaches to study pathway integration:

  • Use PRKD1 (Ab-738) Antibody to monitor total protein levels

  • Combine with phospho-specific antibodies to track activation status

  • Employ pathway-specific inhibitors to dissect interconnections

  • Assess downstream transcriptional targets using reporter assays

Understanding these pathway integrations provides insights into how PRKD1 coordinates complex cellular responses to different stimuli .

What is the detailed composition of PRKD1 (Ab-738) Antibody solution?

The PRKD1 (Ab-738) Antibody is supplied as a purified immunoglobulin with specific formulation characteristics:

• Concentration: 1.0 mg/mL

• Buffer composition: Phosphate buffered saline (PBS) without Mg²⁺ and Ca²⁺

• pH: 7.4

• Salt concentration: 150 mM NaCl

• Preservative: 0.02% sodium azide

• Stabilizer: 50% glycerol

• Form: Liquid

• Isotype: IgG

• Purification method: Affinity-chromatography using epitope-specific peptide

This formulation ensures antibody stability during shipping and storage while maintaining optimal activity for various applications .

What RT-PCR protocols are compatible with PRKD1 expression analysis to complement antibody studies?

When combining PRKD1 protein detection using PRKD1 (Ab-738) Antibody with mRNA expression analysis, the following RT-PCR protocol has been validated:

• RNA extraction:

  • Extract total RNA using standard methods (TRIzol or column-based)

  • Ensure high-quality RNA (A260/280 ratio ~2.0)

• cDNA synthesis:

  • Incubate 1 μg RNA with oligo(dT)18 primer in 10 μl total volume at 70°C for 10 minutes

  • Add 5× buffer, 40 U RNAsin Plus RNase Inhibitor, 200 μM dNTPs, and 1 μl ImProm-II reverse transcriptase to a total volume of 20 μl

  • Incubate at 25°C for 5 minutes, then 42°C for 60 minutes

  • Heat-inactivate at 70°C for 15 minutes

• PCR amplification:

  • Use PRKD1-specific primers:
    Forward: 5′-TTCTCCCACCTCAGGTCATC-3′
    Reverse: 5′-TGCCAGAGCACATAACGAAG-3′

  • Include GAPDH as reference gene:
    Forward: 5′-TCAACGGATTTGGTCGTATTG-3′
    Reverse: 5′-AGAGTTAAAAGCAGCCCTGGTGA-3′

  • PCR conditions: 1 min at 55°C and 1-min extension at 72°C for 35 cycles

• Analysis:

  • Visualize PCR products on 1.5% agarose gel with ethidium bromide staining

  • Quantify relative expression by normalizing to GAPDH

This protocol allows for correlation between mRNA and protein levels, providing comprehensive insight into PRKD1 regulation at both transcriptional and translational levels .

How can methylation-specific PCR be integrated with PRKD1 (Ab-738) Antibody studies?

For investigating epigenetic regulation of PRKD1 expression in conjunction with protein detection:

• Methylation-specific PCR (MSP-PCR) protocol:

  • Extract genomic DNA from samples

  • Perform bisulfite conversion (converts unmethylated cytosines to uracils)

  • Use methylation-specific primers:
    For methylated PRKD1 promoter:
    Forward: 5′-AGAGGGTTAGTCGGGTAGC-3′
    Reverse: 5′-ACGTCCGCGAAATAACTTA-3′
    For unmethylated PRKD1 promoter:
    Forward: 5′-TTTAGGTTGATTTGTAGATGGAAT-3′
    Reverse: 5′-CAATCCACTACTACCCATAACAA-3′

  • PCR conditions: 1 min at 94°C, 35 cycles (30 s at 94°C, 45 s at 50°C, 1 min at 72°C), followed by final extension at 72°C for 10 min

  • Analyze products on 1.5% agarose gel

• Integrating with protein studies:

  • Perform MSP-PCR to determine methylation status

  • In parallel, use PRKD1 (Ab-738) Antibody for Western blotting to assess protein levels

  • Correlate methylation patterns with protein expression

  • For intervention studies, treat cells with demethylating agents (e.g., decitabine)

  • Monitor both methylation status and protein reexpression

This integrated approach has been effectively used to demonstrate that PRKD1 promoter methylation correlates with loss of protein expression in breast cancer progression and that pharmacological reversal of this methylation can restore protein expression and suppress metastatic potential .

What emerging technologies could enhance PRKD1 research beyond traditional antibody applications?

Several cutting-edge technologies hold promise for advancing PRKD1 research:

• CRISPR-Cas9 genome editing:

  • Generate PRKD1 knockout cell lines for loss-of-function studies

  • Create knock-in models with tagged endogenous PRKD1 for live imaging

  • Introduce specific mutations to study structure-function relationships

  • Validate all modifications using PRKD1 (Ab-738) Antibody for protein expression confirmation

• Proximity labeling approaches:

  • BioID or TurboID fusion with PRKD1 to identify proximal interacting proteins

  • APEX2-based labeling to map spatial proteomics in different cellular compartments

  • Validate interactions using co-immunoprecipitation with PRKD1 (Ab-738) Antibody

• Single-cell analysis:

  • Combine PRKD1 (Ab-738) Antibody with mass cytometry for high-dimensional protein analysis

  • Integrate with single-cell transcriptomics to correlate protein and mRNA levels

  • Spatial transcriptomics to map PRKD1 expression in tissue microenvironments

• Optogenetic and chemogenetic tools:

  • Develop light-activated or small molecule-regulated PRKD1 variants

  • Study temporal aspects of PRKD1 signaling with precise activation control

  • Monitor downstream effects using phospho-specific antibodies

These emerging approaches, when combined with traditional antibody-based methods, will provide unprecedented insights into PRKD1 biology and potentially reveal new therapeutic opportunities .

How might PRKD1 (Ab-738) Antibody contribute to translational research and therapeutic development?

PRKD1 (Ab-738) Antibody has significant potential in translational applications:

• Biomarker development:

  • Use in immunohistochemistry panels to assess PRKD1 expression in patient samples

  • Correlate expression patterns with disease progression and treatment response

  • Develop prognostic scoring systems incorporating PRKD1 status

• Drug discovery pipeline:

  • Screen for compounds that modulate PRKD1 expression or activity

  • Evaluate epigenetic modifiers that reverse PRKD1 promoter methylation

  • Assess drug effects on PRKD1 localization using immunofluorescence

• Precision medicine approaches:

  • Stratify patients based on PRKD1 expression status

  • Identify patient populations likely to benefit from PRKD1-targeting therapies

  • Monitor treatment efficacy through serial biopsies

• Therapeutic monitoring:

  • Track PRKD1 reexpression during epigenetic therapy (e.g., decitabine treatment)

  • Correlate protein restoration with clinical outcomes

  • Use as a pharmacodynamic marker in clinical trials

Research has already established that pharmacologic reversion of PRKD1 silencing can block tumor progression and metastasis, suggesting promising therapeutic applications that could be monitored using this antibody .

What methodological innovations could advance the study of PRKD1 in tumor microenvironment interactions?

Understanding PRKD1's role in tumor-stroma interactions requires innovative approaches:

• Multiplex immunofluorescence:

  • Combine PRKD1 (Ab-738) Antibody with markers for immune cells, endothelial cells, and fibroblasts

  • Perform spatial analysis of PRKD1 expression relative to microenvironment components

  • Quantify using digital pathology platforms and machine learning algorithms

• 3D organoid cultures:

  • Establish patient-derived organoids with preserved tumor-stroma architecture

  • Analyze PRKD1 expression patterns using immunofluorescence

  • Manipulate PRKD1 levels to assess effects on organoid formation and invasion

• In vivo imaging approaches:

  • Develop methods to track PRKD1 expression/activity in living organisms

  • Use xenograft models with PRKD1 reporter systems

  • Correlate with metastatic potential using in vivo imaging systems

• Secretome analysis:

  • Investigate how PRKD1 expression affects tumor cell secretome

  • Analyze conditioned media from PRKD1-expressing versus silenced cells

  • Assess impact of secreted factors on stromal cell recruitment and activation

These methodological innovations could reveal new dimensions of PRKD1 biology in the complex ecosystem of tumors, potentially identifying novel intervention points for cancer therapy .